The GH secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats — VialBase Research
medium
- Ipamorelin reversed glucocorticoid-induced bone loss in rats
- Increased bone mineral content and bone formation markers
- Suggests bone-protective applications for GH secretagogues
Summary
Animal study demonstrating that ipamorelin counteracts the negative effects of glucocorticoid therapy on bone formation. Chronic glucocorticoid use is a major cause of secondary osteoporosis, and this study showed that ipamorelin’s GH-stimulating effects could offset steroid-induced bone loss.
Key Findings
- Ipamorelin reversed glucocorticoid-induced decrease in bone formation rate
- Increased bone mineral content in glucocorticoid-treated rats
- Elevated osteocalcin (bone formation marker) levels
- Effects mediated through GH/IGF-1 axis stimulation
- Dose-dependent bone-protective effect observed
- Suggests potential application in steroid-induced osteoporosis prevention
Methodology
Rat study using dexamethasone to induce bone loss, followed by ipamorelin treatment. Outcomes assessed via bone mineral content measurement (DEXA), histomorphometry, and serum bone turnover markers (osteocalcin, CTx) at multiple time points over 8 weeks.
Limitations
- Animal study (rat) — bone metabolism differs from humans
- Glucocorticoid-induced bone loss model — may not apply to age-related osteoporosis
- No comparison with other bone-protective agents (bisphosphonates, etc.)
- Long-term safety of chronic ipamorelin for bone health not established
- GH/IGF-1 elevation for bone carries theoretical cancer risk
Relevance to Content
Adds a bone health dimension to ipamorelin content, beyond the typical body composition/anti-aging narrative. Relevant for content targeting users on corticosteroids or those concerned about bone density. Supports the CJC-1295/Ipamorelin stack narrative for musculoskeletal health.
See Also
- Parent compound: Ipamorelin
- CJC-1295